Peringatan Keamanan

Corifact was studied in an acute toxicity study in mice and rats at doses up to 3550 units per kg and 1420 units per kg, respectively. Repeat dose toxicity was studied in rats at daily doses up to 350 units per kg for a period of 14 days. No signs of toxicity were observed in the single dose and repeat dose studies.

A local tolerance study in rabbits demonstrated no clinical or histopathological changes at the injection site after intravenous, intra-arterial or para-venous administration of Corifact.

A thrombogenicity test was performed in rabbits at doses up to 350 units per kg. Corifact showed no thrombogenic potential at the doses tested.

Factor XIII (human)

DB12909

biotech approved investigational

Deskripsi

Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade FDA Label. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key coagulation factor is essential for management and prevention of bleeding episodes.

Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade. Within the body, FXIII circulates as a heterotetramer composed of 2 A-subunits and 2 B-subunits (A2B2)A32363. When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. As a result, the active transglutaminase from subunit A cross-links fibrin and other proteins resulting in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. This contributes to enhanced platelet and clot adhesion to injured tissue, thereby improving blood coagulation and maintenance of hemostasis A18581.

Other drug products with similar structure and function to Factor XIII (human) include DB09310, which is a recombinant form of the A subunit of human coagulation factor XIII. Compared to Factor XIII (human), which is purified from pooled human plasma, DB09310 is produced through recombinant DNA technology where the target protein is grown in yeast and then isolated FDA Label.

Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency FDA Label. As the half-life of endogenous Factor XIII is long (5-11 days), prophylactic therapy with the replacement of FXIII can be given every 4-6 to maintain hemostasisA32363.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 6.6 ±2.29 days [FDA Label] 6.6 days [A32364]
Volume Distribusi Vss = 51.1 mL/kg (volume of distribution at steady state) [A32364]
Klirens (Clearance) 0.25 ±0.09 mL/hr/kg [FDA Label] 0.25 mL/hr/kg [A32364]

Absorpsi

Tmax = 1.7 ±1.44 hr FDA Label Tmax = 1.72 hr A32364 Cmax = 0.9 ±0.20 units/mL (peak concentration at steady state) FDA Label Cmax = 87.7% (peak concentration at steady state) A32364

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

92 Data
Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Factor XIII (human).
Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor XIII (human).
Menadione Menadione may increase the thrombogenic activities of Factor XIII (human).
Tranexamic acid Tranexamic acid may increase the thrombogenic activities of Factor XIII (human).
Aprotinin Aprotinin may increase the thrombogenic activities of Factor XIII (human).
Hydrogen peroxide Hydrogen peroxide may increase the thrombogenic activities of Factor XIII (human).
Aminomethylbenzoic acid Aminomethylbenzoic acid may increase the thrombogenic activities of Factor XIII (human).
Camostat Camostat may increase the thrombogenic activities of Factor XIII (human).
Menadione bisulfite Menadione bisulfite may increase the thrombogenic activities of Factor XIII (human).
Monteplase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Monteplase.
Lepirudin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Lepirudin.
Bivalirudin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Bivalirudin.
Alteplase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Alteplase.
Urokinase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Urokinase.
Reteplase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Reteplase.
Anistreplase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Anistreplase.
Tenecteplase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tenecteplase.
Abciximab The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Abciximab.
Drotrecogin alfa The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Drotrecogin alfa.
Streptokinase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Streptokinase.
Dicoumarol The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dicoumarol.
Argatroban The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Argatroban.
Ardeparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ardeparin.
Phenindione The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Phenindione.
Fondaparinux The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Fondaparinux.
Warfarin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Warfarin.
Pentosan polysulfate The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Pentosan polysulfate.
Phenprocoumon The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Phenprocoumon.
Dipyridamole The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dipyridamole.
Heparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Heparin.
Enoxaparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Enoxaparin.
Epoprostenol The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Epoprostenol.
Acenocoumarol The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Acenocoumarol.
4-hydroxycoumarin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with 4-hydroxycoumarin.
Coumarin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Coumarin.
Ximelagatran The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ximelagatran.
Desmoteplase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Desmoteplase.
Defibrotide The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Defibrotide.
Ancrod The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ancrod.
Beraprost The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Beraprost.
Prasugrel The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Prasugrel.
Rivaroxaban The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Rivaroxaban.
Sulodexide The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Sulodexide.
Idraparinux The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Idraparinux.
Cangrelor The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Cangrelor.
Astaxanthin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Astaxanthin.
Apixaban The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Apixaban.
Otamixaban The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Otamixaban.
Amediplase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Amediplase.
Dabigatran etexilate The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dabigatran etexilate.
Danaparoid The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Danaparoid.
Dalteparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dalteparin.
Tinzaparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tinzaparin.
(R)-warfarin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with (R)-warfarin.
Ethyl biscoumacetate The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ethyl biscoumacetate.
Nadroparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Nadroparin.
Triflusal The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Triflusal.
Ticagrelor The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ticagrelor.
Ditazole The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Ditazole.
Vorapaxar The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Vorapaxar.
Edoxaban The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Edoxaban.
Sodium citrate The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Sodium citrate.
Dextran The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dextran.
Bemiparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Bemiparin.
Parnaparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Parnaparin.
Desirudin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Desirudin.
Antithrombin Alfa The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Antithrombin Alfa.
Protein C The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Protein C.
Antithrombin III human The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Antithrombin III human.
Letaxaban The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Letaxaban.
Darexaban The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Darexaban.
Betrixaban The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Betrixaban.
Nafamostat The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Nafamostat.
Gabexate The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Gabexate.
Fluindione The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Fluindione.
Protein S human The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Protein S human.
Brinase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Brinase.
Clorindione The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Clorindione.
Diphenadione The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Diphenadione.
Tioclomarol The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tioclomarol.
Melagatran The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Melagatran.
Saruplase The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Saruplase.
(S)-Warfarin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with (S)-Warfarin.
Tocopherylquinone The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tocopherylquinone.
Dabigatran The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dabigatran.
Semuloparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Semuloparin.
Troxerutin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Troxerutin.
Edetic acid The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Edetic acid.
Reviparin The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Reviparin.
Dermatan sulfate The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dermatan sulfate.
SR-123781A The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with SR-123781A.
Limaprost The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Limaprost.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 27019464
    Schroeder V, Kohler HP: Factor XIII: Structure and Function. Semin Thromb Hemost. 2016 Jun;42(4):422-8. doi: 10.1055/s-0036-1571341. Epub 2016 Mar 28.
  • PMID: 19141159
    Hsieh L, Nugent D: Factor XIII deficiency. Haemophilia. 2008 Nov;14(6):1190-200. doi: 10.1111/j.1365-2516.2008.01857.x.
  • PMID: 25458735
    Nugent DJ, Ashley C, Garcia-Talavera J, Lo LC, Mehdi AS, Mangione A: Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia. 2015 Jan;21(1):95-101. doi: 10.1111/hae.12505. Epub 2014 Dec 2.

Contoh Produk & Brand

Produk: 3 • International brands: 1
Produk
  • Corifact
    Solution • 1600 [iU]/20mL • Intravenous • US • Approved
  • Corifact 1250
    Powder, for solution • 1250 unit • Intravenous • Canada • Approved
  • Corifact 250
    Powder, for solution • 250 unit • Intravenous • Canada • Approved
International Brands
  • Fibrogammin P

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul